3D-PHAD^®

C₈₂H₁₅₈N₃O₂₀P

1537.11

NA.25

Vaccination is well-accepted as an effective method to prevent infections by mounting pathogen-specific immune responses prior to the infection. Usually, immunization with vaccine antigens alone is not able to induce robust or long-lasting immune responses — resulting in failure of protective immunity against infections. Thus, adjuvants are required to enhance cellular or humoral immune responses upon immunization. Because vaccine adjuvants using Lipid A have proven to be safe and effective in inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines, Avanti developed Phosphorylated HexaAcyl Disaccharide (PHAD^®), the first fully synthetic monophosphoryl Lipid A available for use as an adjuvant in human vaccines.

3D-PHAD^® has been used:

• as a synthetic adjuvant for respiratory syncytial virus (RSV) vaccine
• as a synthetic adjuvant to prepare hepatitis B virus (HBV) and virus-like particles (VLP)-based human papillomavirus (HPV) vaccines
• in liposome preparation for the generation of army liposome formulation (ALF) for human immunodeficiency (HIV) gp140 antigen immunization studies in mice.

3-deacyl-phosphorylated hexa-acyl disaccharide (3D-PHAD^®) is derived from monophosphoryl lipid A. It is amphiphilic and associates with the virosomal membranes.

For R&D use only. Not for drug, household, or other uses.

3D-PHAD is a registered trademark of Avanti Polar Lipids, Inc.
PHAD is a registered trademark of Avanti Polar Lipids, Inc.

>99% (HPLC)

powder

Avanti Polar Lipids 699852P

dry ice

−20℃

O[C@H]([C@@H](CO[C@@H]([C@@H]1NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](CO)[C@@H](OP([O-])(O)=O)[C@@H]1OC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](O)[C@@H]2NC(C[C@H](O)CCCCCCCCCCC)=O)[C@@H]2O.[NH4+]

2 mL Amber Glass Crimp Cap Vial (699852P-1mg)
2 mL Amber Glass Crimp Cap Vial (699852P-5mg)

13 - Non Combustible Solids